Opportunity Information: Apply for PAR 13 364
Apply for PAR 13 364
- The National Institutes of Health in the education food and nutrition health income security and social services sector is offering a public funding opportunity titled "Development of Assays for High Throughput Screening for Use in Probe and Pre therapeutic Discovery (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.399 Cancer Control 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research 93.859 Biomedical Research and Research Training 93.865 Child Health and Human Development Extramural Research 93.866 Aging Research.
- This funding opportunity was created on Sep 27, 2013 and posted on Sep 27, 2013.
- Applicants must submit their applications by Jan 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Native American tribal governments (Federally recognized) State governments Special district governments Private institutions of higher education City or township governments Independent school districts Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR-13-364, titled "Development of Assays for High Throughput Screening for Use in Probe and Pre-therapeutic Discovery (R01)," supports R01 research projects focused on creating robust, high-quality assays that can be used for high throughput screening (HTS) of small molecule libraries. The central goal is to grow a pipeline of scientifically strong and technically reliable assays that are ready to be run at scale in established screening environments, especially the NIH Molecular Libraries Production Centers Network (MLPCN) under the Molecular Libraries Program (MLP), as well as other qualified academic screening centers. In practical terms, this announcement is aimed at the early, enabling steps of discovery: building assays that make it possible to find chemical matter that can become research probes or very early pre-therapeutic starting points.
NIH emphasizes two major outcomes. First, applicants are expected to develop assays tied to specific biological targets or disease mechanisms that align with the missions of one or more participating NIH Institutes and Centers. These assays should be designed with the clear intent to screen for small molecules that could serve as chemical probes, meaning compounds that help researchers interrogate biology by selectively modulating a target or pathway. The same screening efforts may also yield pre-therapeutic leads, which are not yet drug candidates but could represent promising starting points for later optimization. Second, NIH explicitly encourages applicants to build collaborations with screening centers that already have hands-on expertise running HTS campaigns, since the point is not only to invent an assay on paper but to ensure it can be implemented in real-world HTS workflows and produce credible, reproducible outputs.
A key feature of this opportunity is its focus on novelty. NIH signals that applicants should avoid targets, assay formats, or approaches that have already been heavily pursued elsewhere, and instead propose assays that open up new biological space, enable previously inaccessible targets, or tackle disease mechanisms in fresh ways. This novelty requirement is not just about being different; it is about strengthening the overall national discovery ecosystem by adding assays that meaningfully expand what can be screened and what kinds of probes can be discovered. At the same time, the assays must remain relevant to at least one participating NIH Institute or Center, so the work needs to be anchored in biomedical importance rather than being technology development without a strong disease or biological rationale.
From an administrative and eligibility standpoint, the announcement is a discretionary NIH grant using the R01 mechanism. It does not require cost sharing or matching. Eligible applicants are broad and include many types of U.S. organizations such as public and private institutions of higher education, nonprofits with or without 501(c)(3) status, small businesses, and for-profit organizations (other than small businesses). Government entities at multiple levels can apply as well, including state governments, county governments, city or township governments, special district governments, and independent school districts, along with public housing authorities and Indian housing authorities. The eligibility language also extends to a wide range of mission-driven and designated institutions and organizations, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations where relevant. Importantly, foreign organizations and foreign institutions are eligible, and non-U.S. components of U.S. organizations may apply; foreign components as defined by NIH policy are allowed, which indicates NIH was open to strong assay development efforts regardless of geography as long as they met NIH requirements.
The opportunity was posted on September 27, 2013, with an original and current closing date of January 7, 2017, and an archive date of February 7, 2017, meaning it is no longer active but remains a useful reference for the kind of assay development NIH has historically prioritized in the probe and pre-therapeutic discovery space. The funding opportunity aligns with multiple CFDA program areas across mental health, alcohol, drug abuse and addiction, cancer (spanning prevention through treatment and control), diabetes/digestive/kidney diseases, allergy and infectious diseases, microbiology and infectious diseases, general biomedical research and training, child health and human development, and aging research. That breadth reflects the intent: the assays can address many disease areas, as long as they map clearly to at least one participating Institute or Center mission and are positioned to feed into high throughput screening efforts that generate useful small molecule probes and early lead matter.
For reference, the full announcement was hosted by NIH at http://grants.nih.gov/grants/guide/pa-files/PAR-13-364.html, and NIH listed the NIH Office of Extramural Research (OER) webmaster contacts for access and linking issues (FBOWebmaster@OD.NIH.GOV), underscoring that this was a formal NIH-wide style FOA designed to connect assay innovators with screening infrastructure capable of carrying discoveries forward.
FAQs: NIH PAR-13-364 - Development of Assays for High Throughput Screening for Use in Probe and Pre-therapeutic Discovery (R01)
What is PAR-13-364?
PAR-13-364 is an NIH funding opportunity announcement (FOA) titled "Development of Assays for High Throughput Screening for Use in Probe and Pre-therapeutic Discovery (R01)." It supported R01 research projects focused on developing robust, high-quality assays designed for high throughput screening (HTS) of small molecule libraries.
What is the main purpose of this funding opportunity?
The central purpose was to expand the pipeline of scientifically strong and technically reliable assays that are ready to run at scale in established screening environments. The intent was to enable discovery of small molecules that can become research probes and potentially provide very early pre-therapeutic starting points.
What type of grant mechanism does this opportunity use?
This FOA used the NIH R01 mechanism.
What kinds of projects were supported?
Projects centered on creating assay systems that can be used for HTS against small molecule libraries. The emphasis was on assays tied to specific biological targets or disease mechanisms, with the practical goal that the assay can be implemented in real HTS workflows and generate reproducible outputs.
What is meant by "assays for high throughput screening" in this FOA?
In this context, HTS assays are assay formats and workflows intended to be run at scale to screen large small molecule libraries. The FOA emphasized building assays that are robust and reliable enough to operate in established screening centers rather than being only conceptual or low-throughput laboratory demonstrations.
What were the two major outcomes NIH emphasized for applicants?
NIH emphasized: (1) development of assays connected to specific biological targets or disease mechanisms aligned with one or more participating NIH Institutes and Centers, designed with clear intent to screen for small molecules that could serve as chemical probes (and potentially yield pre-therapeutic leads); and (2) collaboration with screening centers that have hands-on HTS expertise to ensure assays can be implemented in real-world screening campaigns and produce credible, reproducible results.
What is a "chemical probe" as described in the opportunity?
A chemical probe is a small molecule that helps researchers interrogate biology by selectively modulating a target or pathway. The FOA framed probe discovery as a key intended outcome of screening assays developed under this announcement.
What are "pre-therapeutic leads" in the context of this FOA?
Pre-therapeutic leads are early small molecule starting points that are not yet drug candidates, but may represent promising hits or leads for later optimization. The FOA noted that screening efforts aimed at probe discovery may also yield such early lead matter.
Why does the FOA encourage collaboration with screening centers?
The announcement encouraged collaborations because the goal was not just to design an assay, but to ensure it can be executed within established HTS workflows and deliver reproducible, credible screening outputs. Screening centers bring practical experience in running HTS campaigns at scale.
Which screening environments were specifically highlighted?
The FOA highlighted the NIH Molecular Libraries Production Centers Network (MLPCN) under the Molecular Libraries Program (MLP), as well as other qualified academic screening centers, as key environments where assays could be run at scale.
How important was novelty in proposed assays?
Novelty was described as a key feature of the opportunity. NIH signaled that applicants should avoid targets, assay formats, or approaches that have already been heavily pursued, and instead propose assays that open new biological space, enable previously inaccessible targets, or address disease mechanisms in fresh ways.
Does the FOA support technology development without a biomedical rationale?
No. While novelty and assay innovation were emphasized, the work needed to remain relevant to at least one participating NIH Institute or Center mission. The announcement highlighted the need for biomedical importance rather than technology development without a strong disease or biological rationale.
Do proposed targets or disease mechanisms need to align with NIH missions?
Yes. The FOA stated that assays should be tied to specific biological targets or disease mechanisms that align with the missions of one or more participating NIH Institutes and Centers.
Is cost sharing or matching required?
No. The opportunity explicitly stated that it does not require cost sharing or matching.
Who was eligible to apply?
Eligibility was broad and included many types of U.S. organizations, such as public and private institutions of higher education, nonprofits with or without 501(c)(3) status, small businesses, and for-profit organizations (other than small businesses). Various government entities were also eligible, including state, county, city or township governments, special district governments, independent school districts, public housing authorities, and Indian housing authorities.
Were mission-driven and designated institutions specifically included?
Yes. The eligibility language extended to multiple designated and mission-driven institutions and organizations, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs), and faith-based or community-based organizations where relevant.
Are foreign organizations or institutions eligible?
Yes. The FOA stated that foreign organizations and foreign institutions are eligible. It also allowed non-U.S. components of U.S. organizations to apply, and permitted foreign components as defined by NIH policy.
Is this funding opportunity still open?
No. The FOA is no longer active. It was posted on September 27, 2013, had an original and current closing date of January 7, 2017, and an archive date of February 7, 2017.
What disease and research areas did this FOA align with?
The opportunity aligned with multiple CFDA program areas including mental health, alcohol, drug abuse and addiction, cancer (prevention through treatment and control), diabetes/digestive/kidney diseases, allergy and infectious diseases, microbiology and infectious diseases, general biomedical research and training, child health and human development, and aging research.
Does the breadth of aligned CFDA areas mean any disease area could be relevant?
The FOA reflected broad biomedical scope, indicating assays could address many disease areas as long as they clearly mapped to at least one participating NIH Institute or Center mission and were positioned to feed into HTS efforts that generate useful small molecule probes and early lead matter.
Where could applicants find the full announcement?
The full announcement was hosted by NIH at http://grants.nih.gov/grants/guide/pa-files/PAR-13-364.html.
Who was listed for technical issues related to access or linking?
NIH listed the NIH Office of Extramural Research (OER) webmaster contacts for access and linking issues at FBOWebmaster@OD.NIH.GOV.
What role did the NIH Molecular Libraries Program play in this FOA?
The FOA positioned the work as supporting early enabling steps of discovery and highlighted readiness for execution in established screening environments, particularly the MLPCN under the Molecular Libraries Program (MLP), to help move assay ideas into scalable screening campaigns.
What is the practical "end use" of the assays developed under this FOA?
The practical end use was to run the assays in HTS settings to identify small molecules from libraries that could serve as chemical probes and potentially produce early pre-therapeutic leads for later optimization.
How does this FOA describe the discovery stage it supports?
It focused on early, enabling steps of discovery: building assays that make it possible to find chemical matter suitable for research probes and very early pre-therapeutic starting points, rather than later-stage drug development.
Browse more opportunities from the same category: Education Food and Nutrition Health Income Security and Social Services
Next opportunity: Cigarette Tobacco Reference Products Program (UC2)
Previous opportunity: Planning Grants for Pragmatic Research in Healthcare Settings to Improve Diabetes Prevention and Care (R34)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 364
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 364) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIH/PEPFAR Collaboration for Implementation Science (Admin Supp) Apply for PA 14 024 Funding Number: PA 14 024 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: $500,000 |
| Centers for AIDS Research and Developmental Centers for AIDS Research (P30) Apply for PAR 14 041 Funding Number: PAR 14 041 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: $750,000 |
| Empirical Research on Ethical Issues Related to Central IRBs and Consent for Research Using Clinical Records and Data (R01) Apply for RFA OD 14 002 Funding Number: RFA OD 14 002 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Research on Chronic Overlapping Pain Conditions (R01) Apply for PA 14 244 Funding Number: PA 14 244 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| High Throughput Screening (HTS) to Discover Chemical Probes (R01) Apply for PAR 14 284 Funding Number: PAR 14 284 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25) Apply for RFA MD 15 005 Funding Number: RFA MD 15 005 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01) Apply for PA 15 135 Funding Number: PA 15 135 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Exploratory/Developmental Clinical Research Grants in Obesity (R21) Apply for PA 15 163 Funding Number: PA 15 163 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| Diet and Physical Activity Assessment Methodology (R01) Apply for PAR 15 170 Funding Number: PAR 15 170 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Diet and Physical Activity Assessment Methodology (R21) Apply for PAR 15 171 Funding Number: PAR 15 171 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| Opportunities for Collaborative Research at the NIH Clinical Center (U01) Apply for PAR 15 287 Funding Number: PAR 15 287 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: $500,000 |
| Improving Diet and Physical Activity Assessment (R21) Apply for PAR 06 103 Funding Number: PAR 06 103 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| Research on Improving Health Care for Obese Patients (R01) Apply for PA 07 013 Funding Number: PA 07 013 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Biology and Regeneration of the Liver (R01) Apply for PA 07 026 Funding Number: PA 07 026 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| School based Interventions to Prevent Obesity (R01) Apply for PA 07 180 Funding Number: PA 07 180 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Improving Diet and Physical Activity Assessment (R01) Apply for PAR 07 259 Funding Number: PAR 07 259 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Research On Ethical Issues In Human Subjects Research (R01) Apply for PA 07 277 Funding Number: PA 07 277 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Diet Composition and Energy Balance (R01) Apply for PA 07 218 Funding Number: PA 07 218 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Lymphatic Biology in Health and Disease (R01) Apply for PAR 07 420 Funding Number: PAR 07 420 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Human Pluripotent Stem Cell (hPSC) Research Using Non Embryonic Sources (R01) Apply for PA 08 043 Funding Number: PA 08 043 Agency: National Institutes of Health Category: Education Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 364", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.